Fukuoka, 812-0025, Japan
NCT Number: NCT01153997
Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers
This trial is conducted in Japan. The aim of this trial is to investigate the safety profile of recombinant factor XIII (rFXIII) assessed by the occurrence of adverse events in healthy Japanese subjects. In addition pharmacokinetic parameters will be investigated.
Looking for future studies?
Notify MeKey information
Age range
20 year–65 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Good general health based on assessment of medical history, physical examination, ECG (electrocardiogram) and clinical laboratory data at screening, as judged by the physician
- Body mass index (BMI) between 18.0-27.0 kg/m2 (both inclusive)
Exclusion criteria
- The receipt of any investigational products for coagulation factor protein within 6 months prior to trial start (screening)
- Known or suspected allergy to yeast
- Known bleeding or hematologic disorder
- Significant history of alcoholism or drug/chemical abuse as judged by the physician or positive result in the alcohol breath test/screen of drugs at the trial start (screening)
- Smoking more than 10 cigarettes/day or equivalent
- Not able or willing to refrain from smoking whenever required for the trial procedures
- Habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, soft drinks such as cola, chocolate) as judged by the physician
- Excessive consumption of a diet deviating from a normal diet as judged by the physician
- Strenuous exercise as judged by the physician within 4 days prior to trial start (screening)
- Surgery or trauma with significant blood loss (500 mL or more blood) within 3 months prior to trial start (screening)
- Males who are sexually active and not surgically sterilised, who or whose partner are not using adequate contraceptive methods. Adequate contraceptive measures include that the subject uses a condom during intercourse or that the partner practices adequate conception (sterilisation, hormonal intrauterine devices and oral contraceptives).
Treatment and study plan
catridecacog
DrugSingle rFXIII dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
Placebo
DrugSingle rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
Primary outcomes
-
Occurrence of serious adverse events
Time frame: from first trial related activity (visit 1) and up to 28 days (visit 8) after dosing
-
Occurrence of non-serious adverse events
Time frame: from first trial related activity (visit 1) and up to 28 days (visit 8) after dosing
Secondary outcomes
-
AUC (area under the curve) from time zero to 28 days
Time frame: at day 28
Sponsors and collaborators
Lead sponsor
Novo Nordisk A/S
Industry
Registry information
Official study title
A Randomised, Placebo-controlled Single-dose, Parallel-group, Double-blind Trial Evaluating Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Japanese Subjects
Important dates
- Study start
- 2010
- Primary completion
- 2010
- Study completion
- 2010
- First posted
- Jun 30, 2010
- Registry last updated
- Jun 18, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery
NCT00914589
Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Atlanta, Georgia, United States
View Trial DetailsBioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects
NCT01561417
Acquired Bleeding Disorder, Acquired Haemophilia
Paris, France
View Trial DetailsActivated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease
NCT01562574
Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Parkville, Australia
View Trial DetailsSafety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
NCT02239146
Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Tucson, Arizona, United States
View Trial Details